{"id":553645,"date":"2025-11-06T20:41:17","date_gmt":"2025-11-06T20:41:17","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/553645\/"},"modified":"2025-11-06T20:41:17","modified_gmt":"2025-11-06T20:41:17","slug":"new-fda-priority-review-vouchers-go-to-lilly-novo-vertex","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/553645\/","title":{"rendered":"New FDA priority review vouchers go to Lilly, Novo, Vertex"},"content":{"rendered":"<p>WASHINGTON \u2014\u00a0The Food and Drug Administration on Thursday announced the second batch of companies being granted a \u201cCommissioner\u2019s National Priority Voucher,\u201d a ticket to speedier reviews of drug candidates aligned with U.S. priorities.\u00a0<\/p>\n<p>The announcement came as <a href=\"https:\/\/www.statnews.com\/2025\/11\/06\/trumprx-weight-loss-drug-discounts-wegovy-zepbound\/\" target=\"_blank\" rel=\"noopener\">the Trump administration unveiled agreements<\/a> with Eli Lilly and Novo Nordisk to reduce the prices of popular weight loss drugs \u2014\u00a0part of a broader effort to show its interest in delivering medications to Americans faster, and at cheaper prices, than in the past.\u00a0<\/p>\n<p>In return for dropping prices, Novo and Lilly each received a priority review voucher, which guarantees a regulatory decision within one to two months. Those vouchers will be used for an oral version of Novo\u2019s weight loss drug Wegovy, which is already <a href=\"https:\/\/www.prnewswire.com\/news-releases\/fda-accepts-filing-application-for-oral-semaglutide-25-mg-which-if-approved-would-be-the-first-oral-glp-1-treatment-for-obesity-302445232.html\" target=\"_blank\" rel=\"noopener\">under FDA review<\/a>, and Lilly\u2019s orforglipron, an oral weight loss drug based on a <a href=\"https:\/\/www.statnews.com\/2025\/08\/26\/eli-lilly-oral-glp-1-drug-orforglipron-phase-3-trial-results\/\" target=\"_blank\" rel=\"noopener\">different molecule<\/a> than its approved therapy Zepbound.\u00a0\u00a0<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" target=\"_blank\" rel=\"noopener\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/07\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" target=\"_blank\" rel=\"noopener\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" target=\"_blank\" rel=\"noopener\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" target=\"_blank\" rel=\"noopener\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" target=\"_blank\" rel=\"noopener\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"WASHINGTON \u2014\u00a0The Food and Drug Administration on Thursday announced the second batch of companies being granted a \u201cCommissioner\u2019s&hellip;\n","protected":false},"author":2,"featured_media":141396,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[12848,5885,2460,105,4326,5489,31173,16,15],"class_list":{"0":"post-553645","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-biotechnology","9":"tag-drug-development","10":"tag-fda","11":"tag-health","12":"tag-medication","13":"tag-pharmaceuticals","14":"tag-stat","15":"tag-uk","16":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115504695717388520","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/553645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=553645"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/553645\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/141396"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=553645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=553645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=553645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}